Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib

Silvia La Monica; Claudia Fumarola; Daniele Cretella; Mara Bonelli; Roberta Minari; Andrea Cavazzoni; Graziana Digiacomo; Maricla Galetti; Francesco Volta; Maicol Mancini; Pier Giorgio Petronini; Marcello Tiseo; Roberta Alfieri

doi:10.3390/cancers13010006

Retour

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib

Article de revue

Avec comité de lecture

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib

Silvia La Monica, Claudia Fumarola, Daniele Cretella, Mara Bonelli, Roberta Minari, Andrea Cavazzoni, Graziana Digiacomo, Maricla Galetti, Francesco Volta, Maicol Mancini, …

Cancers, Vol.13(1), pp.6-15

22/12/2020

DOI: https://doi.org/10.3390/cancers13010006

PMID: 33374971

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
Créateurs - sans rôle: Silvia La Monica
Claudia Fumarola
Daniele Cretella
Mara Bonelli
Roberta Minari
Andrea Cavazzoni
Graziana Digiacomo
Maricla Galetti
Francesco Volta
Maicol Mancini
Pier Giorgio Petronini
Marcello Tiseo
Roberta Alfieri
Détails de publication: Cancers, Vol.13(1), pp.6-15
Éditeur: MDPI
Identifiants: 99162807509311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM
Langue: English
Type de ressource: Journal article